We added Emerald Health Pharmaceuticals (EHP) to our investment portfolio, and I am excited to be a part of this project. This round is still open to investors.
About Emerald Health Pharmaceuticals
From their own website, the company says
At Emerald Health Pharmaceuticals (EHP) we are focused on the development of a new class of drugs with precise mechanisms of action aimed at bringing innovative therapies to patients to treat diseases with significant unmet medical needs.
Emerald Health Pharmaceuticals (EHP) is a clinical-stage biotechnology company with a portfolio of novel, patented new chemical entities (NCEs), which in preclinical studies, have demonstrated the potential to be disease-modifying in various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with significant unmet medical need.
The company has created two families of new chemical entities, derived from synthetic cannabidiol (CBD) and cannabigerol (CBG). These molecules have been created through rational drug design to modulate specific receptors and physiological pathways in the body, which are validated targets in many serious diseases. With a multi-pronged mechanism of action (MOA), these NCEs are well positioned as first-in-class disease-modifying therapeutic drug candidates for many diseases, which currently have no cure.
Learn more about the investment opportunity HERE.
*This information is not investment or financial advice. RFC is not a financial advising company. Like any investment, there are risks and you could lose some or all of your investment. We encourage everyone to do their own research before investing.